硝苯地平缓释片联合拉贝洛尔对妊娠高血压患者血压水平及亮氨酸氨基转肽酶、脂联素的影响

Effects of nifedipine sustained-release tablets combined with labetalol on blood pressure levels and LAP, APN in patients with hypertension during pregnancy

摘要:

目的 探究硝苯地平缓释片联合拉贝洛尔对妊娠高血压患者血压水平及亮氨酸氨基转肽酶（LAP）、脂联素（APN）的影响。方法 选取2021年3月—2024年3月西北妇女儿童医院120例妊娠高血压患者为研究对象，按信封抽签法随机分为单一组与联合组，各60例。单一组给予拉贝洛尔治疗，联合组给予硝苯地平缓释片联合拉贝洛尔治疗。比较两组治疗效果、治疗前后血压水平、实验室指标、脐动脉血流指标及不良妊娠结局。结果 联合组的治疗效果优于单一组（P <0.05）。治疗后联合组的收缩压（SBP）、舒张压（DBP）均低于单一组（P <0.05）；联合组治疗前后SBP、DBP的差值均大于单一组（P < 0.05）。治疗后联合组的同型半胱氨酸（Hcy）低于单一组，LAP、APN均高于单一组（P <0.05）；联合组治疗前后Hcy、LAP、APN的差值均大于单一组（P <0.05）。治疗后联合组的阻力指数（RI）、搏动指数（PI）、收缩期和舒张末期最大血流速度比值（S/D）均低于单一组（P <0.05）；联合组治疗前后RI、PI、S/D的差值均大于单一组（P <0.05）。两组不良妊娠结局总发生率比较，差异无统计学意义（P >0.05）。结论 硝苯地平缓释片联合拉贝洛尔对妊娠高血压患者血压水平及LAP、APN的影响较为显著。

Abstract:

Objective To explore the effects of nifedipine sustained-release tablets combined with labetalol on blood pressure levels, leucine arylamidase (LAP), and adiponectin (APN) in patients with hypertension during pregnancy.Methods From March 2021 to March 2024, 120 patients with hypertension during pregnancy admitted to our hospital were selected. Using the envelope drawing method, they were randomly divided into a single treatment group (n = 60) and a combined treatment group (n = 60). The single treatment group received labetalol alone, while the combined treatment group received both nifedipine sustained-release tablets and labetalol. The therapeutic effects, blood pressure levels, laboratory indicators, umbilical artery blood flow parameters, and adverse pregnancy outcomes before and after treatment were compared.Results The therapeutic efficacy in the combined treatment group was higher than that in the single-treatment group (P < 0.05). After treatment, the systolic blood pressure (SBP) and diastolic blood pressure (DBP) in the combined group were lower than those in the single-treatment group (P < 0.05); the differences in SBP and DBP before and after treatment were significantly greater in the combined group (P < 0.05). After treatment, the level of homocysteine (Hcy) in the combined group was lower than that in the single-treatment group, while levels of LAP and APN were higher (P < 0.05); the pre- and post-treatment differences in Hcy, LAP, and APN were also significantly greater in the combined group (P < 0.05). Furthermore, the resistance index (RI), pulsatility index (PI), and the systolic/diastolic blood flow velocity ratio (S/D) in the combined group were lower than those in the single-treatment group after treatment (P < 0.05); the differences in RI, PI, and S/D before and after treatment were significantly greater in the combined group (P < 0.05). The comparison of the incidence rates of adverse pregnancy outcomes between the two groups showed no statistically significant differences (P >0.05).Conclusion The combination of nifedipine sustained-release tablets and labetalol has significant effects on blood pressure levels, LAP, and APN in patients with hypertension during pregnancy.